KRAS and hepatocellular carcinoma: First, the tumors harbor gene mutations similar to those frequently observed in human HCC, with oncogenic mutations in TP53 and KRAS induced by activation of the Oncopig transgene, and loss-of-function mutations in PTEN and CDKN2A induced by CRISPR/Cas9.